Graft vs Host Disease (GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Graft vs Host Disease (GVHD) is a pattern of transplant rejection in which donor immune cells mount an immune response against host tissues. GVHD occurs when the donor’s T cells (the graft) view the patient’s healthy cells (the host) as foreign and attack and damage them. Graft-versus-host disease can be mild, moderate or severe. In some cases, it can be life-threatening. The incidence of chronic GVHD ranges from 6% to 80%. GVHD is considered one of the main causes of morbidity and mortality after HCT; more than 10% of patients will die from this complication. Thelansis’s “Graft vs Host Disease (GVHD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graft vs Host Disease (GV